Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anthera Announces Enrollment Of 500th Patient In Francis Trial Of A-002 For The Treatment Of Cardiovascular Disease View HTML
Toggle Summary Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect And LDL Reduction In Patients With Coronary Heart Disease View HTML
Toggle Summary Anthera Pharmaceuticals Advances Global Development Strategy For Varespladib In Patients With Acute Coronary Syndrome With The Initiation Of Francis Trial View HTML
Toggle Summary Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman View HTML
Toggle Summary Anthera presents data on Varespladib at ATVB meeting View HTML
Toggle Summary DSMB supports continuation of Anthera phase II IMPACTS trial for the prevention of acute chest syndrome in patients with sickle cell disease View HTML
Toggle Summary Data From Anthera's PLASMA Trial to be Presented as Late Breaker at American College of Cardiology Scientific Sessions View HTML
Toggle Summary Anthera enters into manufacturing agreements for varespladib in preparation for pivotal Phase III trials View HTML
Toggle Summary Anthera Announces Preliminary Positive Results from Once-Daily A-002 Phase II Cardiovascular Trial View HTML
Toggle Summary Anthera Pharmaceuticals acquires the worldwide rights to a BAFF inhibitor for the treatment of lupus and other autoimmune diseases View HTML